AI assistant
Terns Pharmaceuticals, Inc. — Director's Dealing 2025
Feb 4, 2025
32559_dirs_2025-02-03_9e9d285b-9a57-4730-82bb-ea693fa16a5d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-01-30
Reporting Person: Burroughs Amy L. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-30 | Common Stock | P | 510.00 | $5.11 | Acquired | 19609.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-30 | Stock Option (Right to Buy) | $4.64 | A | 1075000.00 | Acquired | 2035-01-29 | Common Stock (1075000.00) | Direct |
Footnotes
F1: Includes an additional 510 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024 that was not previously reported on the reporting person's Form 4 filed on December 9, 2024 due to an administrative error.
F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.